Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Wei Peng Yong
CONTACT
Lead
National University Hospital, Singapore
This study aims to assess the noninferiority of progression free survival of standard dosing compared to extended dosing interval of nivolumab, pembrolizumab and atezolizumab in advanced/unresectable gastric/gastroesophageal junction/oesphageal adenocarcinomas with PDL1 CPS ≥5%, hepatocellular carcinoma, and non-small cell lung cancer with PDL1 TPS≥50%. Secondary Objective * To investigate the safety, overall survival (OS) of ICI at extended dosing interval of the standard versus extended dosing interval groups. * To investigate the pharmacokinetics (PK) of nivolumab, atezolizumab or pembrolizumab.
Age
21–99
Sex
ALL
Healthy volunteers
Not accepted